BioRestorative Therapies Announces $1.085 Million Registered Direct Offering Priced Above Market Biotech Investing
AMGEN MAKES REPATHA® AVAILABLE THROUGH AMGENNOW, A DIRECT-TO-PATIENT PROGRAM IN THE U.S. Biotech Investing
Avidity Biosciences to Present Data from EXPLORE44® Clinical Development Program of Del-Zota in DMD44 at 30th Annual Congress of the World Muscle Society Biotech Investing
Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson's Patients at International Congress of Parkinson's Disease and Movement Disorders® Biotech Investing
NRx Pharmaceuticals, Inc. to Present at Noble Capital Markets October 2025 Emerging Growth Virtual Equity Conference Biotech Investing
CSL Behring Signs Letter of Intent with pan-Canadian Pharmaceutical Alliance for Public Reimbursement of HEMGENIX® , the First Gene Therapy for Hemophilia B Biotech Investing
Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy in Sanfilippo Syndrome Type B Biotech Investing
Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors Biotech Investing
argenx announces Extraordinary General Meeting of Shareholders on November 18, 2025 Biotech Investing
Cardiol Therapeutics' Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases
